

Figure S1




**Figure S1.** Antibody-mediated inhibition of CTLA4 induces an activated T cell profile in hyperlipidemic mice and does not affect monocyte/macrophage-driven inflammation. (**A, B, C**) Flow cytometry analysis of macrophages and monocytes in the aorta, after  $\alpha$ CTLA4 treatment. There is no difference between the groups. (**D**) In the circulation, flow cytometry analysis indicated an increase in CD8+CD44+CD62L- effector memory cells and an increase in CD4+FoxP3+ regulatory T cells after  $\alpha$ CTLA4 treatment. Other T cell populations and B cells were not affected.

Figure S2:




**Figure S2.** (A) Representative pictures of the en face expression of VE-cadherin on the endothelium of the abdominal aorta. Arrow heads indicate disrupted cell-cell junctions. Scale bar: 10  $\mu$ m. B) Quantification of VE-cadherin continuity by confocal microscopy on the endothelium of the abdominal aorta (n = 3).

## Figure S3



**Figure S3.** Additional immunohistochemical quantifications of the aortic arch. **(A)** Quantification of Ly6G<sup>+</sup> neutrophils in the plaque. **(B)** Quantification of Ki67<sup>+</sup> proliferating cells in the plaque. **(C)** Quantification of TUNEL<sup>+</sup> apoptotic cells.

Figure S4:



**Figure 4.** Additional immunohistochemical quantifications of the aortic root. (**A**) Quantification of Ly6G<sup>+</sup> neutrophils in the plaque. (**B**) Quantification of Ki67<sup>+</sup> proliferating cells in the plaque. (**C**) Quantification of TUNEL<sup>+</sup> apoptotic cells. (**D**) Quantification of  $\alpha$ SMA per plaque phenotype. (**E**) Quantification of MAC3 per plaque phenotype.